Show
Sort by
-
Promises and challenges of single-domain antibodies to control influenza
-
- Journal Article
- A1
- open access
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
-
New antibody-based prevention and treatment options for influenza
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
-
Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice
-
- Journal Article
- A1
- open access
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo
-
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo
-
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry
-
Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection
-
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy